Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Breast Neoplasms 43Neoplasm Metastasis 5Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Stomach Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2HER2-positive Breast Cancer 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Sarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Gemcitabine 87Cisplatin 66Cystectomy 38pembrolizumab 34Docetaxel 25Nivolumab 24durvalumab 21Paclitaxel 19Magnetic Resonance Spectroscopy 18Radiotherapy 17Mitomycin 17Carboplatin 16atezolizumab 15Doxorubicin 14Cystoscopy 14BCG Vaccine 13Surveys and Questionnaires 12Standard of Care 12avelumab 11Sunitinib 10tremelimumab 9Transurethral Resection of Bladder 9Ipilimumab 9Filgrastim 9Blood Specimen Collection 9Specimen Handling 8Neoadjuvant Therapy 8Methotrexate 8Methods 8Early Intervention, Educational 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urinary Bladder Neoplasms × Ado-Trastuzumab Emtansine × Clear all
NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
131 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡